About innate pharma sa - IPHA
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.
IPHA At a Glance
Innate Pharma SA
117, Avenue de Luminy
Marseille, Provence-Alpes-Cote-dAzur 13009
| Phone | 33-4-30-30-30-30 | Revenue | 3.15M | |
| Industry | Pharmaceuticals: Major | Net Income | -55,500,077.88 | |
| Sector | Health Technology | Employees | 163 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
IPHA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 49.846 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.264 |
| Enterprise Value to Sales | 45.464 |
| Total Debt to Enterprise Value | 0.185 |
IPHA Efficiency
| Revenue/Employee | 19,296.606 |
| Income Per Employee | -340,491.275 |
| Receivables Turnover | 0.352 |
| Total Asset Turnover | 0.033 |
IPHA Liquidity
| Current Ratio | 1.275 |
| Quick Ratio | 1.275 |
| Cash Ratio | 0.936 |
IPHA Profitability
| Gross Margin | N/A |
| Operating Margin | -2,058.02 |
| Pretax Margin | -1,987.155 |
| Net Margin | -1,764.514 |
| Return on Assets | -58.835 |
| Return on Equity | N/A |
| Return on Total Capital | -5,438.001 |
| Return on Invested Capital | -484.551 |
IPHA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 2,597.583 |
| Total Debt to Total Assets | 35.991 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 1,584.695 |